Pfizer Inc. will be able to supply the US with 200 million Covid-19 vaccine doses by the end of May, two months sooner than previously expected, according to its top executive.

Chief Executive Officer Albert Bourla said Tuesday that the drugmaker and its partner, BioNTech SE, will be able to deliver the doses to the US well before an earlier July 31 deadline due to a change in the vaccine’s label that allows health-care providers to extract an additional dose from each vial.

The six-dose-per-vial count became effective on Monday and applies to supply contracts going forward, according to a Pfizer representative.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook